



June 12, 2023

Re: New Prescription Drug Notice From Novo Nordisk Inc. – Sogroya®

Submitted via email: AGO.highcostprescriptiondrugs@vermont.gov

Dear Vermont Attorney General Office,

Pursuant to 18 V.S.A. §4637 (b), Novo Nordisk Inc. is providing notification of a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

NDC	Drug Product Description	Introduced to Market Date	WAC at Intro to Market
00169-2035-11	5mg/1.5ML Pen	6/9/2023	\$1,317.90
00169-2030-11	10mg/1.5ML Pen	6/9/2023	\$2,635.80
00169-2037-11	15mg/1.5ML Pen	6/9/2023	\$3,953.70

We will submit to the Department the additional information required under 18 V.S.A. §4637 (b) within 30 days of this initial submission.

Sincerely,

Grant Ostlund
Associate Director, Ethics & Compliance
Novo Nordisk Inc.